ZA987804B - A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist - Google Patents
A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonistInfo
- Publication number
- ZA987804B ZA987804B ZA987804A ZA987804A ZA987804B ZA 987804 B ZA987804 B ZA 987804B ZA 987804 A ZA987804 A ZA 987804A ZA 987804 A ZA987804 A ZA 987804A ZA 987804 B ZA987804 B ZA 987804B
- Authority
- ZA
- South Africa
- Prior art keywords
- agonist
- combination
- monoamine oxidase
- oxidase inhibitor
- ht1b antagonists
- Prior art date
Links
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703376A SE9703376D0 (sv) | 1997-09-18 | 1997-09-18 | A new combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA987804B true ZA987804B (en) | 1999-03-18 |
Family
ID=20408296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA987804A ZA987804B (en) | 1997-09-18 | 1998-08-27 | A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6159970A (et) |
| EP (1) | EP1014986B1 (et) |
| JP (1) | JP2001516719A (et) |
| KR (2) | KR20010024084A (et) |
| CN (1) | CN1278727A (et) |
| AR (1) | AR013503A1 (et) |
| AT (1) | ATE270889T1 (et) |
| AU (1) | AU752719B2 (et) |
| BR (1) | BR9812236A (et) |
| CA (1) | CA2302204A1 (et) |
| DE (1) | DE69825062T2 (et) |
| DK (1) | DK1014986T3 (et) |
| EE (1) | EE200000146A (et) |
| ES (1) | ES2222603T3 (et) |
| HU (1) | HUP0100621A2 (et) |
| ID (1) | ID25789A (et) |
| IL (1) | IL134775A0 (et) |
| IS (1) | IS5401A (et) |
| MX (1) | MXPA00002616A (et) |
| NO (1) | NO20001400L (et) |
| PL (1) | PL339368A1 (et) |
| PT (1) | PT1014986E (et) |
| SE (1) | SE9703376D0 (et) |
| SK (1) | SK2832000A3 (et) |
| TR (1) | TR200000725T2 (et) |
| WO (1) | WO1999013878A1 (et) |
| ZA (1) | ZA987804B (et) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957948A (en) * | 1988-05-05 | 1990-09-18 | Interface, Inc. | Biocidal protective coating for heat exchanger coils |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| WO2002066454A1 (fr) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| EP1408976B3 (en) * | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| JP2009533325A (ja) * | 2006-03-17 | 2009-09-17 | アストラゼネカ・アクチエボラーグ | ５−ｈｔ６調節剤としての新規なテトラリン |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| NZ598685A (en) | 2009-09-11 | 2013-05-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| CN110179988A (zh) * | 2019-07-10 | 2019-08-30 | 王大伟 | 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用 |
| WO2024130044A1 (en) * | 2022-12-14 | 2024-06-20 | Luminous Mind Inc. | Treatment of psychological factors affecting other medical conditions (pfaomc) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69232003T2 (de) * | 1991-09-18 | 2002-04-25 | Glaxo Group Ltd., Greenford | Benzanilidderivate als 5-HT1D-Antagonisten |
| GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
-
1997
- 1997-09-18 SE SE9703376A patent/SE9703376D0/xx unknown
-
1998
- 1998-08-27 ZA ZA987804A patent/ZA987804B/xx unknown
- 1998-09-09 EE EEP200000146A patent/EE200000146A/et unknown
- 1998-09-09 DE DE69825062T patent/DE69825062T2/de not_active Expired - Fee Related
- 1998-09-09 CN CN98811114A patent/CN1278727A/zh active Pending
- 1998-09-09 KR KR1020007002830A patent/KR20010024084A/ko not_active Withdrawn
- 1998-09-09 PT PT98944376T patent/PT1014986E/pt unknown
- 1998-09-09 US US09/171,578 patent/US6159970A/en not_active Expired - Fee Related
- 1998-09-09 BR BR9812236-3A patent/BR9812236A/pt not_active IP Right Cessation
- 1998-09-09 JP JP2000511500A patent/JP2001516719A/ja active Pending
- 1998-09-09 PL PL98339368A patent/PL339368A1/xx unknown
- 1998-09-09 AT AT98944376T patent/ATE270889T1/de not_active IP Right Cessation
- 1998-09-09 MX MXPA00002616A patent/MXPA00002616A/es unknown
- 1998-09-09 EP EP98944376A patent/EP1014986B1/en not_active Expired - Lifetime
- 1998-09-09 TR TR2000/00725T patent/TR200000725T2/xx unknown
- 1998-09-09 ES ES98944376T patent/ES2222603T3/es not_active Expired - Lifetime
- 1998-09-09 CA CA002302204A patent/CA2302204A1/en not_active Abandoned
- 1998-09-09 IL IL13477598A patent/IL134775A0/xx unknown
- 1998-09-09 DK DK98944376T patent/DK1014986T3/da active
- 1998-09-09 KR KR1020007002835A patent/KR20010024087A/ko not_active Ceased
- 1998-09-09 WO PCT/SE1998/001602 patent/WO1999013878A1/en not_active Ceased
- 1998-09-09 ID IDW20000522D patent/ID25789A/id unknown
- 1998-09-09 SK SK283-2000A patent/SK2832000A3/sk unknown
- 1998-09-09 HU HU0100621A patent/HUP0100621A2/hu unknown
- 1998-09-09 AU AU91931/98A patent/AU752719B2/en not_active Ceased
- 1998-09-17 AR ARP980104635A patent/AR013503A1/es unknown
-
2000
- 2000-03-14 IS IS5401A patent/IS5401A/is unknown
- 2000-03-17 NO NO20001400A patent/NO20001400L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2302204A1 (en) | 1999-03-25 |
| IL134775A0 (en) | 2001-04-30 |
| DE69825062D1 (de) | 2004-08-19 |
| EE200000146A (et) | 2001-02-15 |
| AU752719B2 (en) | 2002-09-26 |
| EP1014986A1 (en) | 2000-07-05 |
| US6159970A (en) | 2000-12-12 |
| NO20001400D0 (no) | 2000-03-17 |
| ATE270889T1 (de) | 2004-07-15 |
| DE69825062T2 (de) | 2005-08-25 |
| CN1278727A (zh) | 2001-01-03 |
| EP1014986B1 (en) | 2004-07-14 |
| TR200000725T2 (tr) | 2000-08-21 |
| AU9193198A (en) | 1999-04-05 |
| KR20010024084A (ko) | 2001-03-26 |
| WO1999013878A1 (en) | 1999-03-25 |
| KR20010024087A (ko) | 2001-03-26 |
| PT1014986E (pt) | 2004-10-29 |
| HUP0100621A2 (hu) | 2001-08-28 |
| JP2001516719A (ja) | 2001-10-02 |
| AR013503A1 (es) | 2000-12-27 |
| ID25789A (id) | 2000-11-02 |
| SE9703376D0 (sv) | 1997-09-18 |
| SK2832000A3 (en) | 2000-09-12 |
| IS5401A (is) | 2000-03-14 |
| PL339368A1 (en) | 2000-12-18 |
| BR9812236A (pt) | 2000-07-18 |
| DK1014986T3 (da) | 2004-10-25 |
| ES2222603T3 (es) | 2005-02-01 |
| MXPA00002616A (es) | 2002-04-24 |
| NO20001400L (no) | 2000-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA987804B (en) | A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist | |
| EP1115389A4 (en) | ANTAGONISTS AND AGONISTS OF FRUCTOSAMINE OXIDASE | |
| ZA987817B (en) | A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist | |
| PL337781A1 (en) | Antagonists and reverse antagonists of glucogene | |
| HUP0101809A2 (hu) | 5-és 3-as típusú 17béta-hidroxi-szteroid dehidrogenáz inhibitorok és ezeket tartalmazó gyógyászati készítmények | |
| EG21153A (en) | Use of oil and gasfield chemicals | |
| PL335054A1 (en) | Combination of agents for inhibiting carcinogenesis comprising benzimidazole and possibly a potentiator | |
| ZA974147B (en) | Somatostatin agonists and antagonists. | |
| AU4772497A (en) | Constrained somatostatin agonists and antagonists | |
| PL341335A1 (en) | Combination of ace and mmp inhibitors | |
| IL117988A0 (en) | A new combination of an inhibitor and an antagonist | |
| PL334975A1 (en) | Application of gasto-intestinal lipase inhibitors | |
| HUP9801227A3 (en) | Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use | |
| HU0900792D0 (en) | Use of renin-angiotensin inhibitors | |
| CY2242B1 (en) | Benzonitriles and -fluorides as 5-ht agonists and antagonists | |
| PL337725A1 (en) | Inhibitors of proteases | |
| GB2338014B (en) | Novel drilling device and method of use | |
| EP1069901A4 (en) | CALCILYTIC COMPOUNDS AND THEIR USE | |
| AU6417198A (en) | Cytoprotective agents comprising monoamine oxidase inhibitors | |
| ZA9810272B (en) | Formulation of a cobination of a opioid and a alpha-adrenergic agonist and the use thereof | |
| AU9640698A (en) | Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate | |
| IL134774A0 (en) | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | |
| ZA9710989B (en) | Polyprolyl inhibitors of cyclophilin | |
| PL352387A1 (en) | Pharmaceutical composition containing sibutramine and a lipase inhibitor | |
| HK1032738A (en) | A combination of a monoamine oxidase inhibitor and a h5-ht 1 beta antagonist or partial agonist |